JEFFREY KLOPPER: Open Payments
NPI 1033282017 · SMYRNA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,698 in 126 payments from 17 companies in 2025. Trend: 2023 $3,923 · 2024 $2,848 · 2025 $3,698
Food & beverage: $3,583Education: $115
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 24 | $820 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $682 |
| Alkermes, Inc. | 17 | $501 |
| Teva Pharmaceuticals USA, Inc. | 23 | $434 |
| Vanda Pharmaceuticals Inc. | 14 | $382 |
| Janssen Pharmaceuticals, Inc | 3 | $187 |
| E.R. Squibb & Sons, L.L.C. | 3 | $173 |
| Luye Pharma (USA) Ltd. | 3 | $163 |
| Axsome Therapeutics, Inc. | 4 | $128 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
Products named: INGREZZA, CAPLYTA, FANAPT, ARISTADA, UZEDY, COBENFY, ERZOFRI EXTENDED-RELEASE, Auvelity.
Industry payments across GA — which companies pay providers there.
